The potential of nanomedicine to provide therapeutic benefits over conventional drug formulations has been proven with a number of drugs on the market. Following the success of DOXIL®, a liposome-based doxorubicin formulation which improves pharmakocinetic profile, DIVERSA have developed a new lipidic nanoemulsion. In this post, we look at how it overcomes the barriers of solubility, permeability and intracellular delivery of small molecules, to help biomedical researchers to reach the preclinical stages. Available in Europe through Tebubio, see how DIVERSA’s new technology can redefine the medicinal chemistry/lead screening workflow.

Antibodies and GPCRs. Are they a versatile tool for GPCR pharmacology studies?

GPCRs are encoded by the human genome, some of them have known ligands available which lead to the corresponding radioligands. However, in most cases they are orphan receptors, which means that no ligands are known, or there are only primary antibodies (Abs) available for their study. When directly labelled or using labelled secondary antibodies (indirect immunofluorescence), primary Abs can be used to detect the GPCRs expression through a wide range of techniques, including immunohistochemistry, proximity ligation assays and immunoblotting.

G protein-coupled receptors (GPCRs) represent the largest protein family encoded by the human genome. Located on the cell membrane, they transduce extracellular signals into key physiological effects.^[1]
Considering this feature, they have become highly studied drug targets.

You may have heard about the patented CryostaX^® format of hepatocyte pellets, but do you know why SEKISUI XenoTech and countless other researchers have made the switch from traditional hepatocyte preparations to pellets? Depending on who you ask the reasons will vary, from the needs of the study to simple convenience. In this post, let’s look at the primary factors so you can see for yourself why you should make the switch.